




	Case study: HER2		
	Search results		
3.	■ <u>Records retrieved</u>	April 08	<i>June 08</i>
	Pharmaprojects	77	77
	R&D Focus	76	80
1	R&D Insight	35	39
	Thomson Pharma	60	62
	Prous Integrity	130	136
			BizInt Smart Charts 2008


	Drug	Synonyms	Common Drug Name	Database
126	MAb, HER2/neu, InNexus	DXL 702	DXL 702	IMS R&D Focus
127	DXL-702		DXL 702	PJB Pharmaprojects
128	DXL-702		DXL 702	Prous Integrity Compounds
129	Research programme: anti-HER2 monoclonal antibodies - InNexus Biotechnology	DXL 702 DXL702	DXL 702	Adis R&D Insight










© 2008 BizInt Solutions, Inc. www.bizcharts.com






PJ	PJB Pharmaprojects: PP - HER2 searched by mech and target Product Pharmacological Activity Target Names Search Strate							
83	INSM-18	Insulin like growth factor 1 antagonist (GF-IN-1-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) IGF-1 receptor tyrosine kinase inhibitor (KI-GFIN1-AN)		Mechanism				
84	anticancer MAbs, Xencor-2	CD20 antagonist (CD-20-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN)	membrane-spanning 4-domains, subfamily A, member 1 v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2, neuro/glioblastoma derived oncogene homologue (avian)	Mechanism				
85	T-3100	Oncogene inhibitor (ONCOG-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN) Myc inhibitor (MYC-AN)	v-myc myelocytomatosis viral oncogene homologue (avian) v-erb-b2 erythroblastic leukaemia viral oncogene homologue 3 (avian)	Mechanism				







© 2008 BizInt Solutions, Inc. www.bizcharts.com

